Member Info for Leistertheinvestor

They don’t take it up as quick as they drop it!

Looks like our buyer is still working in the background.

Cashed up into 2026, anyone trying to say a placing is needed before that timeframe will be trying to get in lower.

Looking at todays buying action there's definitely a buyer happily taking decent sized chunks..

I've added again today.

Christmas 2025...

Someone trying to boost the share price with constant narration usually wants to offload shares.

You’ll do better saying nothing JJ7.

UKOG, no chance of getting dilution there haha

Well said JoeCole, he’s instantly blamed for any flurry of sells which could have been anybody or a number of sellers.

Myles contributes very well to any share he holds, his analysis is very thorough and draws good attention to help build volume and momentum, admittedly he’s more bullish when he’s loaded up but hey, we’re all here to make money.

Morning, yes still in and did add a small amount three weeks ago.

Were due an update!

Neodymium should continue to rise as we approach the US elections, if polls suggest a Trump victory is a likely outcome it will reignite concerns with China supply levels and we'll see prices rise quick again?.

US and EU top brains will be discussing with MKA how to get the project(s) mining, processing and recycling working as quickly as possible.

Two delivery systems that are able to get the correct response when delivering siRNA, with an attractive partner (SRI) pushing one of the novel systems forward.

All this for £2m mcap..crazy.

Still high risk obviously but the upside can’t be ignored if one of these systems gets a deal.

Not so many months ago I was told money had run out, the lights were about to be switched off. A crazy fundraise with huge dilution was inevitable.

It didn’t happen, in fact the company released a statement categorically stating online commentators knew what was occurring. They were wrong, they didn’t have a clue, just speculation and pure guessing.

A few individuals are still buying these unloved and unwanted shares although they clearly ain’t shouting about it, yet….

The average AIM punter can’t decide whether they should throw a couple grand at this because they see issues with the drug in the last trial, assuming a repeat outcome is probable . Compare this to Avion Pharmaceuticals who have committed to throw millions at this, as they see previous issues with the last trial was the trial design itself, not the drug.

Many investors and traders made crazy gains on the buildup to the last results, they may not be commenting on this board daily/weekly but be assured, they will be loading up when the trial gets underway.

I also hold out hope for a cure for Chrohns, my Son who is 19 also has this disease, luckily he has very mild symptoms but relies heavily on a six weekly infusion to help him.

I feel we have a good road ahead, sadly time is our biggest hurdle.

Can’t be long, surely?

Last Lupuzor update was one year ago!

Very poor communication Tim.

‘FDA guidance’ is only their preferred trial protocol, the company can show their reasonings for changing the suggested trial design to achieve a better readout, this is what’s happening and clearly the FDA have passed this new design to allow it to go proceed, as they are doing.

Hi, yes I remember you from N4P board, hope your doing okay.

I have added 1.25m shares over the past few sessions only because I can’t risk being out if trial news lands, won’t be adding more until the trial is well underway.

75% reduction in annual overhead costs.. as per RNS on 6th March.

· On 3 June 2024 the Company sold its investment in shares in Incanthera plc. All of the 9,904,319 shares held at the year end were sold at 15p per share realising gross proceeds of £1.4 million. ImmuPharma continues to hold 7,272,740 warrants in Incanthera plc.

Stop feeding the clowns ammo..

I dont know the story with the animosity on here but surely DrMicho should be praising the positive moves today, profits usually move onto other stocks which in turn is helping liquidity across the markets.